Scientific Publications

Androgen Receptor

Miller KJ, Henry I, Maylin ZR, Smith C, Arunachalam E, Pandha H & Asim M.  A compendium of androgen receptor variant 7 target genes and their role in castration-resistant prostate cancer. Front Oncol.2023: Mar 1;13:1129140. doi: 10.3389/fonc.2023.1129140

Nicolescu RCB, Maylin ZR, Pérez-Areales FJ, Iegre J, Pandha HS, Asim M & Spring DR. Hybrid androgen receptor inhibitors outperform enzalutamide and EPI-001 in in vitro models of prostate cancer drug resistance. ChemMedChem. 2022: Oct 27: doi: 10.1002/cmdc.202200548

Miller KJ & Asim M. Unravelling the Role of Kinases that Underpin Androgen Signalling in Prostate Cancer. Cells 2022;11(6):952. doi: 10.3390/cells11060952.

Maylin Z, Nicolescu RCB, Pandha H & Asim M. Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease. Translational Oncology 2021; 14:101115. doi: 10.1016/j.tranon.2021.101115.

Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D’Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE & Asim M.  A reciprocal feedback between the PDZ binding kinase and androgen receptor in prostate cancer.Oncogene 2019; 38(7):1136-1150. doi: 10.1038/s41388-018-0501-z

Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O’Neill C, Zecchini V, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal DE & Helleday T. Synthetic Lethality between androgen signaling and PARP pathway in Prostate Cancer. Nature Communications 2017; 8(1):374. doi: 10.1038/s41467-017-00393-y.

Asim M, Massie CE & Neal DE.  Kinase Joins the Chaperone Club: Androgen-Regulated Kinome Reveals Choline Kinase Alpha as Potential Drug Target in Prostate Cancer.Molecular & Cellular Oncology 2016; 3(3): e1140262.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Selth LA, Zecchini HI, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Zecchini V, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D’Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Baniahmad A, Carroll JS, Griffiths JR, Tavaré S, McEwan IJ, Mills IG, Tilley WD, & Neal DE. Choline kinase alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Journal of National Cancer Institute 2015; 108(5). doi: 10.1093/jnci/djv371

Asim M, Hafeez BB, Siddiqui IA, Gerlach C, Patz M, Mukhtar H & Baniahmad A. Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase.Journal of Biological Chemistry 2011; 286(43):37108-37117. doi: 10.1074/jbc.M111.292771.

Siddiqui IA, Asim M (Joint First),Hafeez BB, Adhami VM, Tarapore RS & Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB Journal 2011; 25(4):1198-1207. doi: 10.1096/fj.10-167924

Eisold M, Asim M, Eskelinen H, Linke T & Baniahmad A. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. J Mol Endocrinol. 2009; 42(5):429-435. doi: 10.1677/JME-08-0084.

Hafeez BB, Asim M, Siddiqui IA, Adhami VM, Murtaza I & Mukhtar H. Delphinidin, a dietary anthocyanidin in pigmented fruits and vegetables: a new weapon to blunt prostate cancer growth. Cell Cycle 2008; 7(21):3320-3326. doi: 10.4161/cc.7.21.6969

Hafeez BB, Siddiqui IA, Asim M, Malik A, Afaq F, Adhami VM, Saleem M, Din M & Mukhtar H.A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling. Cancer Research 2008; 68(20):8564-8572. doi: 10.1158/0008-5472.CAN-08-2232

Khan N, Asim M (Joint First),Afaq F, Abu Zaid M & Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Research 2008; 68(20):8555-8563. doi: 10.1158/0008-5472.CAN-08-0240

Asim M,Siddiqui IA, Hafeez BB, Baniahmad A & Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 2008; 27(25):3596-3604. doi: 10.1038/sj.onc.1211016

Hox genes

Morgan R & Panda HS. PBX3 in Cancer. Cancers 2020, 12: 431. doi: 10.3390/cancers12020431

Idaikkadar P, Morgan R, & Michael A. HOX Genes in High-Grade Ovarian Cancer. Cancers 2019, 11, 1107. doi: 10.3390/cancers11081107

Morgan R, El-Tanani M, Hunter KD, & Pandha HS. Targeting HOX/PBX dimers in cancer. Oncotarget 2017; 8:32322-32331. doi.org/10.18632/oncotarget.15971

Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A, Harrington K, El-Tanani M & Morgan R. Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget 2017;8(52):89566-89579. doi.org/10.18632/oncotarget.20023

Morgan R, Simpson GR, Gray S, Gillett C, Tabi Z, Spicer J, Harrington KJ & Pandha HS. HOX transcription factors are potential targets and markers in malignant mesothelioma. BMC Cancer 2016; 16:85. doi: 10.1186/s12885-016-2106-7

Platais C, Hakami F, Darda L, Lambert DW, Morgan R, Hunter KD. The role of HOX genes in head and neck squamous cell carcinoma. J Oral Pathol Med. 2016; 45: 239-247. doi: 10.1111/jop.12388

Morgan R, Boxall A, Harrington KJ, Simpson GR, Michael A & Pandha HS. Targeting HOX transcription factors in prostate cancer. BMC Urology 2014; 14:17. doi: 10.1186/1471-2490-14-17

Ando H, Natsume A, Senga T, Watanabe R, Ito I, Ohno M, Iwami K, Ohka F, Motomura K, Kinjo S, Ito M, Saito K, Morgan R & Wakabayashi T. Peptide‑based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma. Cancer Chemother Pharmacol 2014; 73:53–60. doi: 10.1007/s00280-013-2316-5

Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS. Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat 2012;136(2):389-398. doi: 10.1007/s10549-012-2259-2

Kelly ZL, Michael A, Butler-Manuel S, Pandha HS, & Morgan RG. HOX genes in ovarian cancer. J Ovarian Res. 2011; 4: 16. doi: 10.1186/1757-2215-4-16

Gray S, Pandha HS, Michael A, Middleton G, & Morgan R. HOX genes in pancreatic development and cancer. JOP 2011; 12: 216-219. PMID: 21546695

Morgan R, Plowright L, Harrington KJ, Michael A, & Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer 2010; 10:89. doi: 10.1186/1471-2407-10-89.

Daniels TR, Neacato II, Rodríguez JA, Pandha HS, Morgan R & Penichet ML. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia 2010; 24(9): 1555–1565. doi: 10.1038/leu.2010.142

Plowright L, Harrington KJ, Pandha HS & Morgan R. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). British Journal of Cancer 2009: 1–6. doi: 10.1038/sj.bjc.6604857